ReviewTherapeutic advances in hematology2014
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.
Review in Therapeutic advances in hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.European journal of clinical pharmacology · 2016Trial
- Advancements in Drug Discovery Techniques for Cancer Treatment: Clinical Progress and Future Directions.Current drug discovery technologies · 2026Review
- Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.International journal of molecular sciences · 2024Review
- The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.International journal of molecular sciences · 2022Article
- Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.Hematological oncology · 2022Article
- Multiple Myeloma: Possible Cure from the Sea.Cancers · 2022Review
- Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.Frontiers in chemistry · 2022Review
- Article
- Updated Understanding of Cancer as a Metabolic and Telomere-Driven Disease, and Proposal for Complex Personalized Treatment, a Hypothesis.International journal of molecular sciences · 2020Review
- Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.Investigational new drugs · 2020Article
- Temporal expression of MOF acetyltransferase primes transcription factor networks for erythroid fate.Science advances · 2020Article
- Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.Annals of hematology · 2019Review
- The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.Oncotarget · 2018Article
- Epigenetic Activation of Pro-angiogenic Signaling Pathways in Human Endothelial Progenitors Increases Vasculogenesis.Stem cell reports · 2017Article
- Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Chinese medical journal · 2017Review
- Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.P & T : a peer-reviewed journal for formulary management · 2016Article
- Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.Journal of medicinal chemistry · 2015Article
- Panobinostat for the treatment of multiple myeloma: the evidence to date.Journal of blood medicine · 2015Review
- The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.